TRUE DILATATION PERCUTANEOUS TRANSLUMINAL VALVULOPLASTY CATHETER, 20MM X 4.5CM, TRUE DILATATION PERCUTANEOUS TRANSLUMINA
Device Facts
| Record ID | K121083 |
|---|---|
| Device Name | TRUE DILATATION PERCUTANEOUS TRANSLUMINAL VALVULOPLASTY CATHETER, 20MM X 4.5CM, TRUE DILATATION PERCUTANEOUS TRANSLUMINA |
| Applicant | Loma Vista Medical |
| Product Code | OZT · Cardiovascular |
| Decision Date | Oct 11, 2012 |
| Decision | SESE |
| Submission Type | Traditional |
| Regulation | 21 CFR 870.1255 |
| Device Class | Class 2 |
| Attributes | Therapeutic, Real-World Evidence |
Real-World Evidence
| Submission | Device | Sponsor | RWD Sources | RWE Use Summary | Key Tags |
|---|---|---|---|---|---|
| K121083 · Oct 11, 2012 | TRUE DILATATION PERCUTANEOUS TRANSLUMINAL VALVULOPLASTY CATHETER, 20MM X 4.5CM, TRUE DILATATION PERCUTANEOUS TRANSLUMINA | Loma Vista Medical | European clinical study records; Post-market surveillance data | Clinical data from 69 procedures and post-market experience from over 400 procedures were used to demonstrate safety, effectiveness, and substantial equivalence to the predicate device. | European clinical studies; Post-market surveillance; Clinical outcomes; Procedural data |
Clinical Evidence
| Study Design | Population | Comparator | Key Endpoints |
|---|---|---|---|
| European clinical studies; Clinical study (observational/routine care) | Patients undergoing balloon aortic valvuloplasty (BAV); Sample Size: 69 procedures | Predicate device (NuCLEUS) | Device performance, procedural data, clinical outcomes, adverse events |
| Post-market surveillance; Post-market surveillance; Study Period: Since European commercial launch | Patients undergoing BAV procedures; Sample Size: >400 procedures | Not applicable for this study | Adverse events |
Indications for Use
The TRUE Dilatation™ Catheter is indicated for balloon aortic valvuloplasty.
Device Story
TRUE Dilatation™ Balloon Valvuloplasty Catheter is a coaxial catheter with a fixed balloon at the tip; used for balloon aortic valvuloplasty (BAV). Input includes radiopaque contrast media delivered via syringe inflation device to inflate the balloon; guidewire used for positioning. Device operated by physicians in clinical settings. Inflation/deflation of balloon dilates the aortic valve; facilitates pre-dilatation prior to TAVI. Output is mechanical dilation of the valve. Benefits include successful valve dilation and preparation for TAVI procedures. Safety and performance confirmed via bench testing and clinical experience.
Clinical Evidence
Two European clinical studies involving 69 procedures were conducted. Data included device performance, procedural outcomes, and clinical safety. Results showed 0/69 adverse events. Clinical experience confirmed successful use for pre-dilatation prior to TAVI. Post-market data from over 400 procedures reported no device failures or device-related adverse events, supporting substantial equivalence to the predicate.
Technological Characteristics
Coaxial catheter design with two lumens (inflation/deflation and guidewire). Materials tested per ISO 10993-1. Mechanical performance verified per ISO 10555-1. Sterilization per ISO 11135-1. Packaging integrity per ASTM D4169. Features include angled luer-lock hub for inflation and straight luer-lock hub for guidewire. Rated for 6 atm maximum inflation pressure; body withstands 30 ATM.
Indications for Use
Indicated for balloon aortic valvuloplasty in patients requiring aortic valve dilation, including pre-dilatation prior to transcatheter aortic valve implantation (TAVI).
Regulatory Classification
Identification
A balloon aortic valvuloplasty catheter is a catheter with a balloon at the distal end of the shaft, which is intended to treat stenosis in the aortic valve when the balloon is expanded.
Special Controls
*Classification.* Class II (special controls). The special controls for this device are:(1) The device must be demonstrated to be biocompatible. (2) Sterility and shelf life testing must demonstrate the sterility of patient-contacting components and the shelf life of these components. (3) Non-clinical performance evaluation must demonstrate that the device performs as intended under anticipated conditions of use, including device delivery, inflation, deflation, and removal. (4) In vivo evaluation of the device must demonstrate device performance, including the ability of the device to treat aortic stenosis. (5) Labeling must include a detailed summary of the device-related and procedure-related complications pertinent to the use of the device.
In combination with the general controls of the FD&C Act, the NuMED NuCLEUS and NuCLEUS-X BAV Catheters are subject to the following special controls:
Predicate Devices
- NuCLEUS (K082776)